Jing-jing Li - Publications

Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study.

Journal: Gut

Published: February 10, 2026

Trajectories of postoperative hepatitis B virus (HBV) DNA and HBV-related hepatocellular carcinoma outcomes.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: June 05, 2024

Dichotomous roles of ADAR1 in liver hepatocellular carcinoma and kidney renal cell carcinoma: Unraveling the complex tumor microenvironment and prognostic significance.

Journal: International immunopharmacology

Published: March 13, 2024

Propensity score matching is recommended for retrospective comparative analysis of sarcopenia's clinical prognostic impact on hepatocellular carcinoma resection patients in Eastern and Western cohorts.

Journal: International journal of surgery (London, England)

Published: January 30, 2024

Multifaceted roles of lymphatic and blood endothelial cells in the tumor microenvironment of hepatocellular carcinoma: A comprehensive review.

Journal: World journal of hepatology

Published: December 10, 2023

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.

Journal: Nature medicine

Published: September 20, 2023

Correction to: PPDPF promotes lung adenocarcinoma progression via inhibiting apoptosis and NK cell-mediated cytotoxicity through STAT3.

Journal: Oncogene

Published: July 26, 2023

Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study.

Journal: Frontiers in immunology

Published: November 26, 2022

PPDPF Promotes the Development of Mutant KRAS-Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 28, 2022

PPDPF suppresses the development of hepatocellular carcinoma through TRIM21-mediated ubiquitination of RIPK1.

Journal: Cell reports

Published: April 18, 2022

ARID2 mitigates hepatic steatosis via promoting the ubiquitination of JAK2.

Journal: Cell death and differentiation

Published: April 08, 2022

PPDPF promotes lung adenocarcinoma progression via inhibiting apoptosis and NK cell-mediated cytotoxicity through STAT3.

Journal: Oncogene

Published: January 31, 2022